Departamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, 30130-100 Belo Horizonte, MG, Brazil.
World J Gastroenterol. 2011 Sep 14;17(34):3916-21. doi: 10.3748/wjg.v17.i34.3916.
To evaluate the treatment of pediatric functional chronic intestinal constipation (FCIC) with a probiotic goat yogurt.
A crossover double-blind formula-controlled trial was carried out on 59 students (age range: 5-15 years) of a public school in Belo Horizonte, MG, Brazil, presenting a FCIC diagnostic, according to Roma III criteria. The students were randomized in two groups to receive a goat yogurt supplemented with 10(9) colony forming unit/mL Bifidobacterium longum (B. longum) (probiotic) daily or only the yogurt for a period of 5 wk (formula). Afterwards, the groups were intercrossed for another 5 wk. Defecation frequency, stool consistency and abdominal and defecation pain were assessed.
Both treatment groups demonstrated improvement in defecation frequency compared to baseline. However, the group treated with probiotic showed most significant improvement in the first phase of the study. An inversion was observed after crossing over, resulting in a reduction in stool frequency when this group was treated by formula. Probiotic and formula improved stool consistency in the first phase of treatment, but the improvement obtained with probiotic was significantly higher (P = 0.03). In the second phase of treatment, the group initially treated with probiotic showed worsening stool consistency when using formula. However, the difference was not significant. A significant improvement in abdominal pain and defecation pain was observed with both probiotic and formula in the first phase of treatment, but again the improvement was more significant for the group treated with B. longum during phase I (P < 0.05). When all data of the crossover study were analyzed, significant differences were observed between probiotic yogurt and yogurt only for defecation frequency (P = 0.012), defecation pain (P = 0.046) and abdominal pain (P = 0.015).
An improvement in defecation frequency and abdominal pain was observed using both supplemented and non-supplemented yogurt, but an additional improvement with B. longum supplementation was obtained.
评估益生菌山羊酸奶治疗儿童功能性慢性肠便秘（FCIC）的效果。
在巴西米纳斯吉拉斯州贝洛奥里藏特的一所公立学校，对 59 名（年龄 5-15 岁）符合罗马 III 标准的 FCIC 诊断学生进行了一项交叉双盲对照试验。学生随机分为两组，每天接受添加 10（9）菌落形成单位/毫升长双歧杆菌（B. longum）（益生菌）的山羊酸奶或仅接受酸奶治疗 5 周（配方）。之后，两组交叉进行另一个 5 周的治疗。评估排便频率、粪便稠度、腹部和排便疼痛。
两组治疗组与基线相比排便频率均有所改善。然而，益生菌治疗组在研究的第一阶段表现出最显著的改善。交叉后观察到反转，当该组用配方治疗时，粪便频率降低。益生菌和配方在治疗的第一阶段改善了粪便稠度，但益生菌的改善更显著（P = 0.03）。在治疗的第二阶段，最初用益生菌治疗的组在使用配方时粪便稠度恶化。然而，差异不显著。益生菌和配方在治疗的第一阶段均显著改善了腹痛和排便痛，但是在第一阶段使用 B. longum 治疗的组改善更显著（P < 0.05）。当分析整个交叉研究的数据时，益生菌酸奶和普通酸奶在排便频率（P = 0.012）、排便痛（P = 0.046）和腹痛（P = 0.015）方面存在显著差异。
补充和非补充酸奶均能改善排便频率和腹痛，但添加 B. longum 可获得额外的改善。
